SCHEMBL3976956

SCHEMBL3976956

CC1(C(=O)O)CN(C(=O)OC(c2ccccc2)C(C)(C)C)CC1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.34
CYP2C9 P11712 5/20 0.34
CYP3A4 P08684 5/20 0.34
CYP2C19 P33261 4/20 0.34
CHRM1 P11229 1/20 0.34
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 4/20 0.32
CYP1A2 P05177 2/20 0.32
MGLL Q99685 1/20 0.32
OPRK1 P41145 1/20 0.32
HIF1A Q16665 2/20 0.31
PAK4 O96013 1/20 0.31
CDK2 P24941 1/20 0.31
MAPK1 P28482 1/20 0.31
GSK3B P49841 1/20 0.31
MARK1 Q9P0L2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975095 1.00 CYP2D6 (0.34) CYP2D6CYP2C9CYP3A4CYP2C19CHRM1
SCHEMBL3979106 0.75 RORC (0.36) CYP2D6CYP2C9CYP3A4CYP2C19CHRM1
SCHEMBL3977469 0.75 RORC (0.36) CYP2D6CYP2C9CYP3A4CYP2C19CHRM1
SCHEMBL3983521 0.75 RORC (0.36) CYP2D6CYP2C9CYP3A4CYP2C19CHRM1
SCHEMBL3978561 0.74 RORC (0.38) CYP2D6CYP2C9CYP3A4CYP2C19MGLL
SCHEMBL3983032 0.73 MEN1 (0.49) CYP2C19GAAMEN1KMT2AL3MBTL1
SCHEMBL31504609 0.69 ALOX15 (0.41) GAAMEN1KMT2AL3MBTL1TSHR
SCHEMBL21372577 0.68 ATM (0.47) CYP2D6CYP3A4KMT2AATML3MBTL1
SCHEMBL21372578 0.68 ATM (0.47) CYP2D6CYP3A4KMT2AATML3MBTL1
SCHEMBL9607539 0.67 ALDH1A1 (0.51) CYP2D6CYP3A4KMT2AATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563805-B2 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-07-21 US disclosed
US-20060264428-A1 Tri-, tetra-substituted-3-aminopyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264428-A1 Tri-, tetra-substituted-3-aminopyrrolidine derivative QTRT1, RRS1, LAS1L CYP2D6 895/4885CYP2C9 1799/4885CYP3A4 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.